Generali Asset Management SPA SGR Buys Shares of 10,197 IQVIA Holdings Inc. (NYSE:IQV)

Generali Asset Management SPA SGR bought a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,197 shares of the medical research company’s stock, valued at approximately $2,004,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Private Trust Co. NA raised its stake in shares of IQVIA by 10.7% during the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after purchasing an additional 47 shares during the period. Pine Valley Investments Ltd Liability Co raised its stake in shares of IQVIA by 0.5% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock valued at $2,247,000 after purchasing an additional 50 shares during the period. Howard Capital Management Inc. raised its stake in shares of IQVIA by 4.9% during the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock valued at $225,000 after purchasing an additional 54 shares during the period. Wealth Enhancement Advisory Services LLC raised its stake in shares of IQVIA by 1.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock valued at $1,068,000 after purchasing an additional 56 shares during the period. Finally, Cypress Wealth Services LLC raised its stake in shares of IQVIA by 4.8% during the 4th quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company’s stock valued at $244,000 after purchasing an additional 57 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently issued reports on IQV shares. UBS Group decreased their price objective on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Stephens assumed coverage on IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 target price for the company. Robert W. Baird reduced their target price on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, January 21st. Royal Bank of Canada restated an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research report on Monday, February 10th. Finally, Citigroup reduced their target price on IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Five equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Trading Down 0.9 %

NYSE IQV opened at $186.80 on Thursday. IQVIA Holdings Inc. has a 1-year low of $179.28 and a 1-year high of $256.29. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a 50-day moving average of $195.71 and a 200-day moving average of $209.36. The firm has a market cap of $32.93 billion, a PE ratio of 24.91, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.